Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced hair loss despite using Fin and Min for 12 years and switched to Dutasteride, RU58841, and Keto scalp serum, but shedding and itch persist. They are considering increasing Dutasteride to 2.5mg and questioning the necessity of a scalp biopsy, with mixed opinions on its usefulness.

A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

A user's 8 month progress with treatments including dutasteride, minoxidil, RU58841, derma roller, ketoconazole shampoo and stemoxydine to combat hair loss. Others have shared their own experiences and regrowth results with similar treatments.

Users discuss alternatives to DHT blockers for hair loss, suggesting minoxidil, microneedling, natural DHT blockers, and scalp massages. Some explore RU58841, ketoconazole, hair transplants, and hair systems due to side effects from finasteride and dutasteride.

A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

Creatine may increase DHT levels, potentially affecting hair loss, but evidence is mostly anecdotal. A study to explore this was withdrawn due to funding issues.

Switching from tretinoin to tazarotene with minoxidil led to new hair regrowth after years of maintenance. Tazarotene's selectivity and higher concentration might be more effective for hair growth.

A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.

The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.

A user is considering a hair transplant combined with dutasteride and oral minoxidil to improve results despite having a large bald area. They seek advice on whether this combination is worth trying.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.

A 29-year-old male shared his hair loss journey, using oral finasteride, topical minoxidil, derma rolling, and recently switching to dutasteride, oral minoxidil, and ketoconazole shampoo. He observed significant regrowth but progress slowed, hoping new treatments will enhance results.

Combining finasteride and dutasteride with activities that raise testosterone may increase the risk of side effects like gynecomastia, depending on genetic predisposition and hormone levels. It's advised to check hormone levels to assess the risk.

The effects of smoking cigarettes on DHT levels and its potential effect on hair loss, with some people sharing experiences in relation to their own hair loss. Various treatments for reducing or reversing hair loss were discussed, such as quitting smoking, minoxidil, finasteride and RU58841.

The conversation is about a user's one-year hair loss treatment using dutasteride, oral and topical minoxidil, ketoconazole, tretinoin, and PRP. Users discuss treatment effectiveness, potential issues with diffuse thinning, and sourcing affordable treatments.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

A 29-year-old male experiencing hair loss due to TRT is using minoxidil and dermarolling but is hesitant to use finasteride or dutasteride due to potential side effects. He is considering low level laser therapy (LLLT), PRP, ketoconazole shampoo, and oral minoxidil as additional treatments. A reply suggests that without a DHT blocker like finasteride or dutasteride, other treatments may not be effective long-term.

The conversation discusses the effectiveness of using 2.5 mg Dutasteride daily versus combining 0.5 mg Dutasteride with 150 mg RU58841 for reducing scalp DHT. Opinions vary, with some users recommending lower doses of Dutasteride and cautioning against RU58841 due to potential side effects.

The user underwent a hair transplant and was prescribed dutasteride and minoxidil for 6 months to address crown thinning. They are skeptical about the short duration and consider continuing the medication longer.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

The conversation discusses the potential for high doses of dutasteride to completely inhibit scalp DHT and speculates whether this could cure baldness when combined with a topical antiandrogen. Specific dosages mentioned are 0.5 mg reducing scalp DHT by 55% and 2.5 mg by about 79%.

Dutasteride and finasteride are not effective for everyone in treating hair loss, with some users experiencing worsening conditions. Many are hopeful for new treatments like PP405, while others consider hair transplants or alternative medications.

The user has been using a combination of treatments including Dutasteride, Minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy to address hair loss but continues to experience shedding and density loss. Despite high testosterone and iron levels, the user is frustrated with the lack of improvement and is considering adjusting treatment or exploring other options like a hair transplant.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

A user experienced significant hair shedding after 8 months of using oral dutasteride (0.5 mg), minoxidil (2.5 mg), and biotin (5 mg) daily. They are concerned about the effectiveness of the treatment and possible resistance to dutasteride.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.